Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith D Eaton

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Palliative Medicine|December 1, 2021
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint InhibitorsCameron Chalker, Rafael Santana-Davila, Jenna M Voutsinas, et al.
Advances in Radiation Oncology|April 7, 2022
Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung CancerStephen R Bowen, Daniel S Hippe, Hannah M Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trialRenato G Martins, Upendra Parvathaneni, Julie E Bauman, et al.
The Journal of Molecular Diagnostics : JMD|November 6, 2013
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimensColin C Pritchard, Stephen J Salipante, Karen Koehler, et al.
Medrxiv : the Preprint Server for Health Sciences|March 31, 2025
Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancerNatalie J Miller, Christina S Baik, Joel W Neal, et al.
Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.
Journal for Immunotherapy of Cancer|July 15, 2025
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancerNatalie J Miller, Christina Baik, Joel W Neal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2011
NCCN Clinical Practice Guidelines Occult primaryDavid S Ettinger, Mark Agulnik, Justin M M Cates, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Occult primary, version 3.2014David S Ettinger, Charles R Handorf, Mark Agulnik, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Palliative Medicine|December 1, 2021
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint InhibitorsCameron Chalker, Rafael Santana-Davila, Jenna M Voutsinas, et al.
Advances in Radiation Oncology|April 7, 2022
Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung CancerStephen R Bowen, Daniel S Hippe, Hannah M Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trialRenato G Martins, Upendra Parvathaneni, Julie E Bauman, et al.
The Journal of Molecular Diagnostics : JMD|November 6, 2013
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimensColin C Pritchard, Stephen J Salipante, Karen Koehler, et al.
Medrxiv : the Preprint Server for Health Sciences|March 31, 2025
Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancerNatalie J Miller, Christina S Baik, Joel W Neal, et al.
Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.
Journal for Immunotherapy of Cancer|July 15, 2025
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancerNatalie J Miller, Christina Baik, Joel W Neal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2011
NCCN Clinical Practice Guidelines Occult primaryDavid S Ettinger, Mark Agulnik, Justin M M Cates, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Occult primary, version 3.2014David S Ettinger, Charles R Handorf, Mark Agulnik, et al.
Pageof 6